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ABSTRACT
Introduction: This study explored patients’ and
dermatologists’ priority outcomes for treatment
to address, clinical outcome assessments (COA)
for use in vitiligo clinical trials, and perceptions
of within-patient meaningful change in facial
and total body vitiligo.
Methods: Semistructured, individual, qualitative
interviews were conducted with patients living
with non-segmental vitiligo in the USA and with
expert dermatologists in vitiligo. Concept elicitation discussions included open-ended questions
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to identify patient priority outcomes. Vitiligo
COAs were reviewed by dermatologists. Tasks were
completed by patients to explore their perceptions
of meaningful changes in vitiligo outcomes; dermatologists’ opinions were elicited. Data were
analyzed using thematic methods; meaningful
change tasks were descriptively summarized.
Results: Individuals with vitiligo (N = 60)
included adults (n = 48, 63% female) and adolescents (n = 12, 67% female). All Fitzpatrick Skin
Types were represented. Eight (13%) were first- or
second-generation immigrants to the USA.
Expert dermatologists (N = 14) participated from
the USA (n = 8), EU (n = 4), India (n = 1), and
Egypt (n = 1). All individuals with vitiligo reported experiencing skin depigmentation; an
observable clinical sign of vitiligo. Most confirmed that lesion surface area (n = 59/60, 98%)
and level of pigmentation (n = 53/60, 88%) were
important to include in disease assessments.
Following an explanation, participants (n = 49/
60, 82%) felt that the Facial Vitiligo Area Scoring
Index (F-VASI) measurement generally made
sense and understood that doctors would use it to
assess facial vitiligo. Most participants felt that a
75% (n = 47/59, 80%) or 9 0% improvement in
their facial vitiligo would be indicative of treatment success (n = 55/59, 93%). In the context of
evaluating a systemic oral treatment for vitiligo,
dermatologists perceived a 75% improvement on
the F-VASI as successful (n = 9/14, 64%).
Regarding the Total VASI (T-VASI) score, n = 30
participants considered 33% improvement as
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treatment success; an additional n = 10 endorsed
50% improvement and a further n = 5 endorsed
75% improvement. Clinicians most frequently
identified 50% (n = 6/14, 43%) or 75% (n = 4/14,
29%) improvement in T-VASI as successful.
Conclusion: Repigmentation is a priority outcome for patients. The VASI was considered an
appropriate tool to assess the extent of vitiligo. A
minimum 75% improvement from baseline in
the F-VASI and minimum 50% improvement
from baseline in the T-VASI were identified as
within-patient clinically meaningful thresholds.
Keywords: Vitiligo; Quality of life; Qualitative
research; Outcome measurement; Vitiligo area
scoring index
Key Summary Points
The Vitiligo Area Scoring Index (VASI) is a
clinician-reported outcome that assesses
affected body surface area and level of
depigmentation. Research to date has
identified different treatment-success
thresholds through different methods of
inquiry. However, a definition for success
is still required for evaluating vitiligo
treatments.
This study used innovative, qualitative
methods to explore patients’ and
dermatologists’ perspectives on priority
outcomes for vitiligo treatment to address,
clinical outcome assessments (COAs) to
measure those outcomes in vitiligo clinical
trials, and perceptions of meaningful
within-patient changes in vitiligo outcomes.
The study confirmed that repigmentation is
an outcome of priority for vitiligo patients.
The VASI was considered an appropriate
tool to assess the extent of vitiligo in clinical
trials for vitiligo treatments.
A minimum 75% improvement from
baseline in the Facial Vitiligo Area Scoring
Index (F-VASI) and minimum 50%
improvement from baseline in the T-VASI
were identified as clinically meaningful
thresholds endorsed by individuals living
with vitiligo.
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INTRODUCTION
Vitiligo is a chronic autoimmune disease characterized by white macules due to melanocyte
destruction [1]. Vitiligo can be limited in extent
or involve multiple body sites and large body
surface area (BSA) [2]. The Vitiligo Area Scoring
Index (VASI) is a clinician-reported outcome
(ClinRO) that assesses affected BSA and level of
depigmentation [3]. The VASI yields a single
score for the body [sometimes referred to as
Total Body VASI (T-VASI)]. Recent clinical trials
have assessed vitiligo involvement of the face,
i.e., the Facial VASI (F-VASI) score, separate
from the body, i.e., the T-VASI [4]. The VASI has
demonstrated high inter- and intra-observer
reliability scores, [5] and the F-VASI and T-VASI
have demonstrated strong test–retest reliability,
known-groups validity, and responsiveness to
change [4].
One hand unit (i.e., the palm plus the volar
surface of all fingers; * 1% of the total body
surface area) is used to measure the extent of
vitiligo involvement of several body regions,
including the head and neck, hands, upper
extremities, trunk, lower extremities, and feet
[4]. The extent of depigmentation within each
affected lesion is assessed using predefined percentages: 0%, 10%, 25%, 50%, 75%, 90%, or
100%. The T-VASI is calculated using
R½Handunits  ½ResidualDepigmentation, and is
summed (RÞ for all body regions. The face, and
therefore F-VASI, contributes 3–3.5% of the
total BSA [4, 6] and is included in the T-VASI
score.
To execute patient-focused drug development, patients’ experiences, perspectives, and
priorities must be meaningfully incorporated
into the evaluation of medical products [7–10]
via well-defined and reliable (i.e., fit-for-purpose) clinical outcome assessments (COAs). An
important component of fit-for-purpose evidence is content validity, i.e., evidence that the
COA measures what matters to patients [8]. In
the context of vitiligo, it is important for
stakeholders to understand: (1) what are the
most important vitiligo treatment outcomes for
patients living with nonsegmental vitiligo, and
(2) the level of improvement that constitutes
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clinical benefit from the patient perspective.
Intuitively we understand that achieving 100%
repigmentation would be a clinical treatment
success. However, when repigmentation is less
than 100%, we need to understand what
patients consider to be meaningful treatment
benefit [11].
The Vitiligo Global Issues Consensus Conference (VGICC) explored treatment success
with dermatologists, patients/caregivers, and
healthcare professionals through an eDelphi
study. Findings indicated that treatment of a
single lesion was successful if repigmentation
exceeded 80% and at least 80% of the gained
repigmentation was maintained for [ 6 months
[12]. The International Initiative for Outcomes
(INFO) for vitiligo conducted clinician-led
workshops with patients or their caregivers. The
consensus for the definition of ‘‘successful
repigmentation’’ from the patient perspective
was 80% to 100% of repigmentation of a single
lesion [13]. Furthermore, patients found
achieving C 25%
repigmentation
after
3 months of treatment to be a satisfactory
intermediate result, where they would be willing to continue treatment [13]. The face, neck,
and hands were considered the most important
locations to achieve satisfactory results [13].
Rosmarin et al. [4] explored clinically meaningful change in F-VASI and T-VASI using an
anchor-based approach with phase 2 data, and
concluded that a 57% reduction in F-VASI and a
42% reduction in T-VASI were considered clinically meaningful. F-VASI75 (75% reduction
from baseline) and T-VASI50 (50% reduction
from baseline) thresholds were proposed to
ensure that phase 3 endpoints set a higher bar
for treatment success than those determined by
anchor-based analyses.
Research to date has identified different
treatment-success thresholds through various
methods, and mainly focused on level of
repigmentation only. A definition for success is
still required for evaluating vitiligo treatments
and was a recent topic of discussion in the FDAled Patient Focused Drug Development (PFDD)
Meeting for Vitiligo [11]. A within-patient
meaningful change threshold is typically confirmed through anchor-based analyses but can
also be informed by qualitative exploration,
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seeking direct input from patients and experts
to explore not only what the threshold should
be, but also the impact that this change may
have on how patients feel and function[14].
The objectives of this study were to conduct
systematic, qualitative, semistructured interviews with individuals living with vitiligo and
expert clinicians, to:
1.

2.

3.

4.

Identify the vitiligo treatment outcomes of
priority that are most meaningful and most
important to improve for defining clinical
benefit from the patient and clinician perspectives, including the development of a
Vitiligo Consequence Model.
Further explore the percentage change in
repigmentation that patients with vitiligo
consider necessary for successful treatment
of both the face and body, specifically the
F-VASI and T-VASI.
Document the impact of vitiligo on how
patients feel and function, the results of
which are reported elsewhere [15].
Meet regulators’ requirement [8] for direct
input from vitiligo patients to provide
definitive supportive evidence for priority
treatment outcomes and what constitutes
meaningful changes for vitiligo.

The qualitative evidence generated from this
research can be used to: (a) document meaningful outcomes to patients, e.g., addressing
depigmentation as an outcome of priority to
patients, and (b) establish clinically meaningful
changes in outcomes from the patient perspective. The current study was specific to the VASI
scoring approach as a whole (including both
repigmentation and surface area in the score),
and ensures understanding of what a meaningful change is for patients in both their facial
vitiligo and their total body vitiligo.

METHODS
This study was a noninterventional, cross-sectional, qualitative interview study. The study
protocol was approved by WIRB-Copernicus
Group independent review board (WCG IRB).
The methodology is illustrated in Supplementary Material 1.
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Interviews with Individuals Living
with Vitiligo
Eligibility Criteria
Individuals were eligible to participate if
aged C 12 years, US residents, and had nonsegmental, active vitiligo, with lesions on the face
and/or body affecting 4–60% of their total BSA
with at least 0.25% BSA on their face, according
to their most recent clinician assessment. Individuals were excluded if they had segmental or
mixed vitiligo, were enrolled in a vitiligo clinical trial, or had active comorbid inflammatory
skin disease. Following 4 months of recruitment, the eligibility criteria were amended to
include adolescents with either 4–60% BSA
impacted by vitiligo or C 0.25% BSA on the
face.
Purposive sampling targeted a representative
sample, including each of the six Fitzpatrick
Skin Types (FSTs) and with different education
levels, an important consideration when evaluating outcome measures (Supplementary Material 2).
Recruitment
Participants were identified via specialist
recruiters (Global Perspectives), clinical sites
(Northwest Dermatology Institute, Oregon and
Dawes-Fretzin Dermatology, Indianapolis) or
advertisements (via The Global Vitiligo Foundation). Individuals provided written informed
consent/assent. Eligibility was confirmed via a
clinician-completed case report form (CRF).
Demographic information was collected via a
self-report screener.
Interview Procedures
Interviews took place between November
2020–March 2021, during the COVID-19 pandemic. To avoid risk, all interviews were conducted remotely. Using a semi-structured
interview guide, interviews were conducted by
trained, qualitative interviewers and lasted
approximately 2 h.
Concept elicitation [16, 17] was utilized to
explore the impact of vitiligo. Open-ended
questions were designed to elicit concepts for a
Vitiligo Consequence Model spontaneously,
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followed by in-depth probe questions on concepts of interest. Questions explored patients’
perspectives on the priority outcomes of vitiligo
for treatment to address, measurement of these
outcomes, and the types of changes that they
consider meaningful for treatment success.
Next, the F-VASI scoring approach was
explained using a visual aid (Fig. 2), utilizing the
most recently published definition of the face
area [4].The measurement components of the
VASI (e.g., affected BSA and level of depigmentation) were described to patients to elicit their
feedback as to whether the components measured their priorities.
The interviewer then introduced activities to
explore meaningful change representative of
clinical benefit from the patient perspective.
Participants were asked about times when their
vitiligo improved and worsened. Next, they
were shown five ‘‘before and after treatment’’
photographs of faces with different improvements in depigmentation. The photos were
‘‘real’’ images (i.e., not digitally altered) of
individuals’ facial vitiligo taken before and after
participating in a clinical trial. To protect the
individuals’ privacy, the images are not included in this publication. Improvement in
depigmentation and surface area on the images
were determined by two raters, using the VASI
scoring system. The photographs of facial vitiligo included representation of at least two FST
skin types.
Patients were then shown illustrative graphics for percentage change (from different baseline scores) to facilitate their understanding and
inform their decision making (Fig. 3). After
viewing the provided examples, patients were
asked to consider treatment success for themselves and their own vitiligo experience, e.g.,
what percentage change (improvement) in
depigmentation would be indicative of treatment success?
Interviews with Expert Clinicians
Sampling and Recruitment
International expert clinicians were selected
from a list provided by the study sponsor (Pfizer), on the basis of their experience in vitiligo
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research and clinical trials. All clinicians signed
an informed consent form (ICF) before
participating.

RESULTS

Interview Procedures
One-hour interviews were conducted remotely
using screen share software, allowing international participation and avoiding COVID-19
exposure risks. Interviewers used a semi-structured interview guide including open-ended
questions with follow-up probes to explore
clinicians’ experience treating individuals with
vitiligo. Clinicians discussed vitiligo assessment
in clinical practice and clinical trials, including
the use of ClinROs (e.g., the VASI). Then, clinicians were asked to state the percentage change
from baseline on the F-VASI and T-VASI that
they would consider to be a treatment success in
the context of a systemic, oral treatment.

Sixty individuals living with vitiligo (n = 48
adults and n = 12 adolescents) (Table 1) participated. Most participants were female. Representation of lower education levels was
achieved. The sample included eight participants who were first- or second-generation living in the USA. No FST group was significantly
over- or under-represented; each group
accounted for 10–23% of the total sample.
Under the expanded enrollment criteria, one
adolescent had vitiligo on their body only and
one had vitiligo on their face only. Additional
sample characteristics are provided in Supplementary Material 3.
Fourteen expert clinicians were recruited,
including from the USA (n = 8), Europe (n = 4)
and the rest of the world (n = 2); most worked at
university-affiliated hospitals, and some had
previously developed vitiligo-specific ClinRO
measures.

Analysis of Interviews
Weekly interviewer meetings were held to discuss interview findings, aid consistency in
approach, and inform interview guide updates.
All interviews were audio recorded and transcribed verbatim. Transcripts were analyzed
using ATLAS.ti version 7.5.
Meaningful change activities were subject to
framework analysis, whereby a pre-defined code
list was applied to identify percentage changes
considered meaningful in F-VASI and T-VASI
scores. Frequency counts summarized patients’
responses. The research team identified the
percentage improvement that appeared to be
indicative of treatment success on the basis of
the frequency of responses at each level that
most participants perceived as successful and
few perceived as unsuccessful.
Steering Committee
A steering committee comprising two clinical
experts in vitiligo and a patient advocate guided
this research. The steering committee members
reviewed the patient interview guide, clinician
interview guide and/or interpreted the study
results.

Sample

Concept Elicitation
All individuals living with vitiligo (n = 60/60)
reported experiencing areas of skin depigmentation, the cardinal clinical sign of vitiligo.
Depigmentation was also reported as a key sign
by all expert clinicians.
•

•

‘‘I’ve had pretty much all of my life that I can
remember, and it’s, err, large, white areas all
over me.’’ (male, 14 years old)
‘‘Non-segmental vitiligo, you will see depigmented patches, so, lack of pigmentation or
skin coloring.’’ (US clinician)

When discussing desired treatment benefits,
over half of individuals with vitiligo (n = 39/60,
65%) reported that they would specifically want
skin repigmentation to occur, and many reported wanting a decrease in the skin surface area
of vitiligo (n = 29/60, 48%), and/or a reduction
in the noticeability of vitiligo (n = 23/60, 38%).

Dermatol Ther (Heidelb) (2022) 12:1623–1637
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Table 1 Sample characteristics (N = 60)
Characteristic

Adults
(N = 48)
n (%)

Adolescents
(N = 12)
n (%)

Total
(N = 60)
n (%)

Female

30 (63%)

8 (67%)

38 (63%)

Male

18 (38%)

4 (33%)

22 (37%)

39.6 (37) [18–62]

14.2 (13.5) [12–17]

34.5 (34) [12–62]

Caucasian or white

27 (56%)

8 (67%)

35 (58%)

Black or African American

6 (13%)

2 (17%)

8 (13%)

Hispanic, Latino, or Spanish origin

4 (8%)

1 (8%)

5 (8%)

Asian

5 (10%)

–

5 (8%)

Other

6 (13%)

1 (8%)

7 (12%)

Asia

4 (8%)

–

4 (7%)

Middle East

2 (4%)

1 (8%)

3 (5%)

Africa

–

1 (8%)

1 (2%)

Self-reported demographic characteristics (N = 60)
Sex

Age, years
Mean (median) [range]
Ethnicity

First or second generation living in the USA, from the
following areas

Total: 8 (13%)
Education (highest level completed)
High school diploma or equivalent

9 (19%)

Bachelor’s degree

16 (33%)

Graduate degree

10 (21%)

Associate degree

7 (15%)

Other

6 (13%)

–

–

1 (8%)

–

Current school grade
6th

–

7th

1 (8%)

8th

5 (42%)

9th

1 (8%)

11th

2 (17%)

12th

1 (8%)
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Table 1 continued
Characteristic

Adults
(N = 48)
n (%)

Adolescents
(N = 12)
n (%)

Total
(N = 60)
n (%)

13.5 (10.9) [0.1–40.9]

5.7 (4.6) [0.5–12.0]

11.9 (10.5) [0.1–40.9]

19.6 (8.40) [4.0–60.0]

12.9 (4.5) [2.1–60.0]

18.3 (7.5) [2.1–60.0]

1.10 (0.75) [0.25–3.00]

0.78 (0.58) [0.00–3.00]

1.00 (0.70 [0.00–3.00]

I

8 (17%)

1 (8%)

9 (15%)

II

10 (21%)

1 (8%)

11 (18%)

III

10 (21%)

4 (33%)

14 (23%)

IV

8 (17%)

4 (33%)

12 (20%)

V

5 (10%)

1 (8%)

6 (10%)

VI

7 (15%)

1 (8%)

8 (13%)

Clinician-reported clinical characteristics (N = 60)
Time since diagnosis, years
Mean (median) [range]
BSA% body
Mean (median) [range]
BSA% face
Mean (median) [range]
Fitzpatrick Skin Type (FST)

Responses included: one-half Black or African American, one-half Hispanic; Middle Eastern; Mexican/Italian; Biracial:
Black and white; Asian and White; Persian; Afghan (each n = 1)

•

•

‘‘Maybe more, um, like, um, like normal
skin, rather than having, like, vitiligo.’’ (female, 13 years old)
‘‘Um, well, the pigment reoccurring in the
areas where it’s gone away.’’ (male, 57 years
old)

Individuals with vitiligo identified their face
(n = 52/60, 87%), hands (n = 42/60, 70%), and
legs (n = 21/60, 35%) among the top three most
bothersome locations of vitiligo; the face was
considered the most important area for a treatment to improve (n = 40/54, 74%). Expert clinicians also identified the face (n = 14/14, 100%)
and hands (n = 13/14, 93%) as the areas they
perceived to be most bothersome to individuals
living with vitiligo.
A Vitiligo Consequence Model is presented
in Fig. 1 and full concept elicitation findings are
reported separately.

Conceptual Relevance of the VASI
The F-VASI and T-VASI scoring was explained to
all individuals living with vitiligo (using the
illustrative graphic in Fig. 2). Nearly all confirmed that lesion surface area (n = 59/60, 98%)
and level of pigmentation (n = 53/60, 88%)
were important disease characteristics to
include in vitiligo assessments.
Most participants felt the F-VASI (n = 49/60,
82%) and T-VASI (n = 54/60, 90%) scoring made
sense, and understood that doctors would use
this to assess the level of vitiligo. When asked if
anything was missing from the F-VASI scoring
process or the facial definition presented [4], n =
16 patients (n = 16/53 asked, 30%) reported that
eyelids and lips should be included in the
F-VASI assessment.
All expert clinicians were familiar with use of
the VASI in research, although only two used it
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Fig. 1 Vitiligo Consequence Model

in clinical practice. Clinicians perceived the
VASI to be a validated framework for assessing
vitiligo (n = 8), and noted it as an advantage
that both affected surface area and level of
depigmentation are included in the scoring
(n = 5). Noted disadvantages included: the VASI
can be time consuming and somewhat difficult
to use (n = 7), and the scoring approach may be
subject to human error or rater discrepancy
(n = 6).
Meaningful Change Thresholds: F-VASI
Participants (n = 59) viewed photographs of
individuals with facial vitiligo ‘‘before and after
treatment,’’ representing 50%, 75%, and 90%
improvements from baseline within different
FSTs, to assist their conceptualization of percentages changes on the F-VASI. To protect the
privacy of the individuals in the photographs,
the images have not been included in this
publication.
Participants also viewed illustrative graphics
depicting 50%, 75%, and 90% improvement,

with each level of change illustrated using three
different baseline scores on the F-VASI (example
in Fig. 3). After reviewing the graphics, individuals were asked to consider the F-VASI
improvement that would be a treatment success
in the context of their own vitiligo experience.
Over half of participants (n = 39/59, 66%)
felt that a 50% improvement from baseline in
their own facial vitiligo would be indicative of
treatment success. However, 12 patients (21%)
stated that 50% improvement in facial vitiligo
would not be indicative of treatment success, as
they perceived that there would still be visible
vitiligo on their face.
•

‘‘If somebody said, ‘We can reduce the, the
depigmentation by 50%,’ I don’t think 50%
would really make too much of a difference
in terms of my face, um, because it would
still leave quite a bit covered. And, again, I
don’t know if it would seem so worth it to
me.’’ (female, 48 years old)

Most participants felt that a 75% (n = 47/59,
80%) or 90% improvement (n = 55/59, 93%)

Dermatol Ther (Heidelb) (2022) 12:1623–1637
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Fig. 2 Example of F-VASI scoring shown to patients

would be indicative of treatment success
(Table 2). Patients felt that both levels of
improvement would lead to less visible areas of
vitiligo and subsequently would alleviate the
emotional and social impacts experienced.
•

•

‘‘I feel like at 75% it’s getting to, um, kind of
a, a, a big degree of change that it’s almost,
kind of, as a whole, being reduced so much.
Whereas 50% is, um—it could still be, err,
large chunks, um, no matter, kind of, where
you started.’’ (male, 22 years old)
[Describing a 90% improvement] ‘‘It would
mean the world of difference. I’d be able to
do so many more things that I don’t do now.
No more makeup, no more coverup. Not
afraid to go next to somebody. Not afraid,
not afraid of the coverup coming off and
destroying somebody’s shirt, or whatever. I
would be, I would be extremely happy.’’
(female, 59 years old)

Only 5% of participants felt that a 75%
improvement was not indicative of treatment
success; noting that it would be an improvement but not a definitive success. The research
team concluded that a minimum 75%
improvement from baseline was indicative of
treatment success on the basis of the frequency

of responses at each level that most participants
perceived as successful/somewhat successful
and few perceived as unsuccessful.
Sub-group analysis compared responses
between adults and adolescents (Supplementary
Material 4). Adults were less likely to endorse
the lower thresholds; however, endorsement of
the highest percentage improvement levels was
broadly consistent between adults and
adolescents.
Most queried participants (n = 24/32, 75%)
indicated that they would be happy with a 50%
improvement in their facial vitiligo after
12 months of treatment; slightly more would be
happy with a 75% improvement (n = 26/32,
81%) or a 90% improvement (n = 24/26, 92%).
Participants expected a 75% improvement in
their own facial vitiligo would reduce the
emotional impact of vitiligo (n = 11), stop vitiligo being noticed by others (n = 4), reduce
need for concealment (n = 4), reduce social
impacts of vitiligo (n = 3), and/or reduce need
for sun protection (n = 3).
•
•

‘‘Um, more confidence, more self-esteem,
more higher self-esteem.’’ (female, 24)
‘‘No more coverup. I’ll be able to socialize a
little more.’’ (female, 59)

1632
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Fig. 3 Interview guide excerpt: F-VASI meaningful change illustrative graphic depicting 75% improvement on the F-VASI

Expert clinicians provided the percentage
change from baseline in F-VASI that they would
consider a treatment success in the context of a
systematic oral treatment (Fig. 4). Nine of the
14 clinicians provided the most frequent
response of 75% improvement from baseline
(range 50–90%). Some clinicians noted that
50% improvement could be achieved through
currently available topical treatments, and
therefore, a greater improvement should be
expected from an oral systemic treatment,
considering the potential risks.
Meaningful Change Thresholds: T-VASI
Participants (n = 50) were asked whether a 33%,
50%, or 75% improvement from baseline on the
T-VASI would be indicative of a treatment success (Table 2). Most considered 33% improvement (n = 30) as treatment success; an
additional n = 10 participants endorsed 50%
improvement, and n = 5 participants endorsed
75% improvement. Eleven participants noted
that 33% improvement would not be a success.
Subgroup analysis compared responses between

adults and adolescents (Supplementary Material
4).
Therefore, the research team identified a
minimum 50% improvement from baseline as
indicative of treatment success on the basis of
the frequency of successful/somewhat successful responses compared with the frequency of
unsuccessful responses. Participants expected a
50% improvement in their own total body
vitiligo to reduce the emotional impacts associated with vitiligo (n = 5), and/or reduce the
need to conceal vitiligo with clothing (n = 2),
improve intimacy, and reduce sun protection
efforts (each n = 1).
Expert clinicians identified the percentage
change from baseline in T-VASI that would be
considered a treatment success (Fig. 4). The
most frequent response was a 50% improvement from baseline (n = 6/14, 43%), followed
by a 75% improvement (n = 4/14, 29%). All
clinicians who suggested a 50% improvement
considered this outcome to be acceptable after
6 months of treatment, although two clinicians
said it was only acceptable if an even greater
percentage improvement was later achieved
(e.g., after 12 months).
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Table 2 Perception of percentage change from baseline on the F-VASI and T-VASI
Yes—treatment
success, N (%)

Somewhat
successful, N (%)

No—not a
success, N (%)

Other*, N (%)

Not asked N (%)

50% improvement

39 (66%)

2 (3%)

12 (21%)

5 (9%)

1 (2%)

75% improvement

47 (80%)

6 (10%)

3 (5%)

–

3 (5%)

90% improvement

55 (93%)

–

1 (2%)

–

3 (5%)

33% improvement

30 (50%)

5 (8%)

11 (18%)

4 (7%)

10 (17%)

50% improvement

10 (17%)

2 (3%)

5 (8%)

1 (2%)

42 (70%)

75% improvement

5 (8%)

1 (2%)

2 (3%)

–

52 (87%)

F-VASI

T-VASI

*Other refers to participants who felt their response would be dependent on the end result, or on characteristics of a
treatment
Not all participants discussed each level owing to time constraints, and ten participants did not participate in this task

DISCUSSION
This study explored meaningful treatment outcomes for patients with nonsegmental vitiligo.
The first objective was to identify the vitiligo
outcomes that are most meaningful to patients,
and the overall priority outcome is repigmentation. Most patients thought it was most
important for a treatment to improve the vitiligo on their face. As an observable clinical sign,
it is appropriate that vitiligo should be assessed
by clinicians with training relevant to the
measurement of BSA and depigmentation. The
VASI scoring and component measurement
concepts (surface area and depigmentation)
were confirmed to assess what individuals living
with vitiligo consider to be important. Comprehensive training is required for the VASI.
While most interviewed clinicians considered it
to be a useful assessment tool, some noted the
time commitment, difficulty, and risk of human
error worth consideration.
The second objective was to explore the
percentage change in depigmentation that
patients with vitiligo consider necessary for
successful treatment. Previous research suggested that a successful treatment would
involve 80% repigmentation of a single lesion
[12, 13], with limited evidence regarding

meaningful change [4] on the F-VASI and
T-VASI. In the current study, patients were
shown photos of full body regions (face or total
body) rather than a single lesion, encouraging
them to consider multiple lesions. This may
have allowed patients to perceive changes in
affected BSA in addition to depigmentation.
The results of the current study suggest that a
minimum 75% improvement from baseline on
the F-VASI can be considered a meaningful
treatment success for individuals living with
vitiligo, as endorsed by most individuals living
with vitiligo (over 6 months or 12 months of
treatment) and expert clinicians. Additionally,
results suggest that a minimum 50% improvement from baseline on the T-VASI can be considered a meaningful treatment success for
individuals living with non-segmental vitiligo;
similarly, half of the expert clinicians also
endorsed 50% improvement from baseline as a
treatment success.
These findings should be considered in the
context of current treatment options in vitiligo;
expert clinicians discussed what could be
achieved with existing narrowband UVB and
topical treatments, and suggested that newer,
systemic treatments should achieve that same
threshold at a minimum. As treatments become
more efficacious, the perception and expectation of what is successful and meaningful may
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Fig. 4 F-VASI% and T-VASI% that represents success for
a systemic, oral treatment.
*Note that for T-VASI Clin_01 proposed a range of
25–50%, the lowest score is shown here. Clin_09 proposed

a range of 70–80%, the lowest score is shown here,
Clin_07 noted that 75% could be minimally successful, but
only if the patient could progress to 90%, therefore the
higher score is shown here

also change. Therefore, the VASI success
thresholds proposed from this study are not
definitive or fixed; instead, the thresholds
reflect current perspectives on vitiligo treatment
options and a potential future oral, systemic
treatment.
Strengths of this study include the involvement of a multi-disciplinary team including
clinical experts, COA, and qualitative research
experts, and a patient advocate who actively
and collaboratively sought to remain patientcentric, inform knowledge gaps, and mitigate
potential researcher bias. It is also a strength
that qualitative interview methods were utilized
to provide insights into the level of change that
is truly important and meaningful for the target
population in clinical trials [14] and for

dermatologist experts in the treatment of vitiligo. Conceptual saturation, defined as the
point at which no new concept-relevant information is identified, was achieved, suggesting
that an adequate sample of individuals living
with vitiligo (N = 60) were included in the
study. Furthermore, quota sampling was utilized to ensure representation of key characteristics within the sample (e.g., FSTs, education
level, gender). On the basis of these considerations, the sample size is aligned with industry
recommendations [18, 19].
Methodological limitations are also noted.
The eligibility criteria required at least 0.25%
BSA on the face, and all adults and almost all
adolescents met this criterion. This may have
skewed the body areas ranked as most
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bothersome, although the findings were aligned
with previous research that identified the face
and hands as important areas for achieving
satisfactory treatment [13]. Demographically,
58% of the sample were white or Caucasian.
However, patients in all six FST groups were
represented; no FST group was considered to be
over- or under-represented, with each ranging
between 10% and 23% of the total sample.
Additionally, no substantial differences were
noted between FST groups. Future research may
build upon this study further, and confirm that
the meaningful change thresholds identified are
generalizable to individuals with vitiligo. However, Ezzedine et al. [20] reports cross-cultural
validation of a short-form of the vitiligo impact
patient scale (VIPs) for light skin types (FSTs
I–III) and for dark skin types (FSTs IV–VI). Furthermore, several studies have observed that
individuals of all FSTs with vitiligo experience
psychosocial burden [21, 22].
Interview activities relating to the VASI
scoring were complex, particularly on the
T-VASI where ‘‘before-and-after’’ treatment
images were not available. To address this,
interviewers spent time explaining each activity
in patient-friendly language and allowed participants time to absorb the information.
Interviewers challenged any obvious discrepancies in interpretation to seek consistent participant comprehension. While it cannot be
guaranteed that all participants understood the
complexities of the F-VASI and T-VASI scoring,
based on interviewer feedback, patients
demonstrated sufficient understanding to
meaningfully participate in each activity.
Therefore, all data were retained in the analyses.
The images representing percentage changes in
VASI scores were simple in design (Fig. 3), and
the location of the ‘‘lesion’’ remained fixed to
allow patients to consider the percentage itself,
not the location of the vitiligo. Additionally,
owing to time constraints, not all participants
discussed each percentage change. A conservative approach was taken to provide exact counts
in the results. However, it can be inferred that
those patients who think 75% improvement is
successful would also consider a 90% improvement is successful.
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This study was conducted within a US sample. While first- or second-generation participants living in the USA from the Middle East,
Asia, or Africa (Table 1; * 13% of total sample)
were included, these findings would need to be
confirmed in other countries and cultures. In
addition, various subcultures within the USA
need to be identified and queried to explore
differences.
This
study
qualitatively
incorporated
patients’ and clinicians’ perspectives to explore
a threshold for defining within-patient meaningful change. FDA PFDD Draft Guidance [16]
notes that interviews can be complementary to
anchor-based methods to inform responder
definitions in clinical trials. A next step is to
confirm
these
thresholds
quantitatively
through anchor-based analyses using appropriate anchor item(s). These thresholds may
eventually be useful in clinical practice.

CONCLUSIONS
Repigmentation is an outcome of priority for
individuals living with vitiligo. The VASI was
considered an appropriate tool to assess the
extent of vitiligo in clinical trials for vitiligo
treatments. A minimum 75% improvement
from baseline in the F-VASI and minimum 50%
improvement from baseline in the T-VASI were
identified as within-patient clinically meaningful thresholds endorsed by individuals living
with vitiligo.
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